Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Ovarian Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 70 articles: HTML format Text format

Single Articles

March 2010
1. TATE AR , Nicholson A, Cassell JA
   Are GPs under-investigating older patients presenting with symptoms of ovarian cancer? Observational study using General Practice Research Database.
   Br J Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   February 2010
2. LEE JM , Sarosy GA, Annunziata CM, Azad N, et al
   Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
   Br J Cancer. 2010;102:495-9.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
3. FALASCA M , Chiozzotto D, Godage HY, Mazzoletti M, et al
   A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
   Br J Cancer. 2010;102:104-14.
   PubMed     Text format     Related articles    Abstract available
   
   
   November 2009
4. BARTON CA , Gloss BS, Qu W, Statham AL, et al
   Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.
   Br J Cancer. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. ZHONG W , Celli JP, Rizvi I, Mai Z, et al
   In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring.
   Br J Cancer. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. TAMEZ S , Norizoe C, Ochiai K, Takahashi D, et al
   Vitamin D receptor polymorphisms and prognosis of patients with epithelial ovarian cancer.
   Br J Cancer. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
7. YOKOTA N , Koizume S, Miyagi E, Hirahara F, et al
   Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells.
   Br J Cancer. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. STUMPF M , Hasenburg A, Riener MO, Jutting U, et al
   Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes.
   Br J Cancer. 2009;101:1513-21.
   PubMed     Text format     Related articles    Abstract available
   
   
   October 2009
9. KONECNY GE , Glas R, Dering J, Manivong K, et al
   Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
   Br J Cancer. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   September 2009
10. CHAN DW , Liu VW, To RM, Chiu PM, et al
    Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21(WAF1/CIP1) expression in ovarian cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. SHEHATA M , Mukherjee A, Deen S, Al-Attar A, et al
    Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. CUNNINGHAM JM , Vierkant RA, Sellers TA, Phelan C, et al
    Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. FERRANDINA G , Sallustio G, Fagotti A, Vizzielli G, et al
    Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
14. WHITE NM , Mathews M, Yousef GM, Prizada A, et al
    KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. IIJIMA H , Patrzyc HB, Budzinski EE, Freund HG, et al
    A study of pyrimidine base damage in relation to oxidative stress and cancer.
    Br J Cancer. 2009;101:452-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
16. DING X , Mohd AB, Huang Z, Baba T, et al
    MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.
    Br J Cancer. 2009;101:269-77.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. SHEACH LA , Adeney EM, Kucukmetin A, Wilkinson SJ, et al
    Androgen-related expression of G-proteins in ovarian cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. CHEN H , Hao J, Wang L, Li Y, et al
    Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. LEE YK , Choi E, Kim MA, Park PG, et al
    BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
20. AHN J , Moore SC, Albanes D, Huang WY, et al
    Height and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. VANDENPUT I , Van Calster B, Capoen A, Leunen K, et al
    Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. VASS SO , Jarrom D, Wilson WR, Hyde EI, et al
    E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
    Br J Cancer. 2009;100:1903-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. FERRUCCI LM , Cross AJ, Graubard BI, Brinton LA, et al
    Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. DE GRAEFF P , Crijns AP, de Jong S, Boezen M, et al
    Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. MONTAGNANA M , Lippi G, Danese E, Franchi M, et al
    Usefulness of serum HE4 in endometriotic cysts.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles   
    
    
    May 2009
26. COUMBOS A , Sehouli J, Chekerov R, Schaedel D, et al
    Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
27. HUHTINEN K , Suvitie P, Hiissa J, Junnila J, et al
    Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. CHENG WF , Huang CY, Chang MC, Hu YH, et al
    High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. STEELE N , Finn P, Brown R, Plumb JA, et al
    Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
    Br J Cancer. 2009;100:758-63.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
30. TRINH XB , Tjalma WA, Vermeulen PB, Van den Eynden G, et al
    The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. QUAYE L , Song H, Ramus SJ, Gentry-Maharaj A, et al
    Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. SHARMA R , Graham J, Mitchell H, Brooks A, et al
    Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. DAY JM , Foster PA, Tutill HJ, Newman SP, et al
    BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.
    Br J Cancer. 2009;100:476-86.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. RAY-COQUARD I , Weber B, Cretin J, Haddad-Guichard Z, et al
    Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
35. PEARCE CL , Near AM, Van Den Berg DJ, Ramus SJ, et al
    Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
36. METCALFE KA , Finch A, Poll A, Horsman D, et al
    Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. COLOMIERE M , Ward AC, Riley C, Trenerry MK, et al
    Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. BAER HJ , Hankinson SE, Tworoger SS
    Body size in early life and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.
    Br J Cancer. 2008;99:1916-22.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
39. VASSILEVA V , Moriyama EH, De Souza R, Grant J, et al
    Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. NAKAYAMA N , Nakayama K, Yeasmin S, Ishibashi M, et al
    KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. KUMARAN GC , Jayson GC, Clamp AR
    Antiangiogenic drugs in ovarian cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. GONCALVES V , Jayson G, Tarrier N
    A longitudinal investigation of psychological morbidity in patients with ovarian cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. SINGH RK , Lange TS, Kim KK, Singh AP, et al
    Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
44. MAHNER S , Baasch C, Schwarz J, Hein S, et al
    C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.
    Br J Cancer. 2008;99:1269-75.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
45. KITCHENER HC
    Survival from cancer of the ovary in England and Wales up to 2001.
    Br J Cancer. 2008;99 Suppl 1:S73-4.
    PubMed     Text format     Related articles   
    
    
    
46. COOPER N , Quinn MJ, Rachet B, Mitry E, et al
    Survival from cancer of the ovary in England and Wales up to 2001.
    Br J Cancer. 2008;99 Suppl 1:S70-2.
    PubMed     Text format     Related articles   
    
    
    
47. OSORIO A , Pollan M, Pita G, Schmutzler RK, et al
    An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2008;99:974-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
48. OIKONOMOPOULOU K , Li L, Zheng Y, Simon I, et al
    Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. NTOUROUPI TG , Ashraf SQ, McGregor SB, Turney BW, et al
    Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope.
    Br J Cancer. 2008;99:789-95.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
50. PONNUSAMY MP , Singh AP, Jain M, Chakraborty S, et al
    MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells.
    Br J Cancer. 2008;99:520-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
51. MULHOLLAND HG , Murray LJ, Cardwell CR, Cantwell MM, et al
    Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis.
    Br J Cancer. 2008;99:434-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2008
52. DE GRAEFF P , Crijns AP, Ten Hoor KA, Klip HG, et al
    The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
    Br J Cancer. 2008;99:341-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. YEUNG BH , Wong KY, Lin MC, Wong CK, et al
    Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2.
    Br J Cancer. 2008;99:283-93.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2008
54. O'BRIEN PM , Davies MJ, Scurry JP, Smith AN, et al
    The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
    Br J Cancer. 2008;98:1880.
    PubMed     Text format     Related articles   
    
    
    
55. LEUNG EL , Fraser M, Fiscus RR, Tsang BK, et al
    Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance.
    Br J Cancer. 2008;98:1803-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
56. WERNLI KJ , Newcomb PA, Hampton JM, Trentham-Dietz A, et al
    Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity.
    Br J Cancer. 2008;98:1781-3.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. VASEY PA , Gore M, Wilson R, Rustin G, et al
    A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
    Br J Cancer. 2008;98:1774-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2008
58. FERRANDINA G , Petrillo M, Carbone A, Zannoni G, et al
    Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.
    Br J Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. CALCAGNO AM , Fostel JM, To KK, Salcido CD, et al
    Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
    Br J Cancer. 2008;98:1515-24.
    PubMed     Text format     Related articles    Abstract available   Free Full Text
    
    
    April 2008
60. LIM SL , Smith P, Syed N, Coens C, et al
    Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
    Br J Cancer. 2008;98:1452-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2008
61. O'BRIEN PM , Davies MJ, Scurry JP, Smith AN, et al
    The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.
    Br J Cancer. 2008;98:1085-93.
    PubMed     Text format     Related articles    Abstract available
    
    
    
62. WRIGHT JD , Doan T, McBride R, Jacobson JS, et al
    Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival.
    Br J Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
63. CHAN JK , Fuh K, Shin JY, Cheung MK, et al
    The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?
    Br J Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
64. ANTONIOU AC , Cunningham AP, Peto J, Evans DG, et al
    The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
    Br J Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
65. AHMED N , Riley C, Quinn MA
    An immunohistochemical perspective of PPARbeta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours.
    Br J Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
66. GOTO T , Takano M, Hirata J, Tsuda H, et al
    The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers.
    Br J Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2008
67. YANG X , Fraser M, Abedini MR, Bai T, et al
    Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt.
    Br J Cancer. 2008;98:803-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
68. FRUSCIO R , Colombo N, Lissoni AA, Garbi A, et al
    A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
    Br J Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2008
69. PEARCE CL , Wu AH, Gayther SA, Bale AE, et al
    Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis.
    Br J Cancer. 2008;98:282-288.
    PubMed     Text format     Related articles    Abstract available
    
    
    
70. ALAM SM , Fujimoto J, Jahan I, Sato E, et al
    Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.
    Br J Cancer. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: